Burning Rock Biotech

Burning Rock Biotech is a China biotech company that primarily develops and provides cancer therapy selection tests. The company was founded in 2014 and is headquartered in Guangzhou, China.
Burning Rock Biotech stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Burning Rock Biotech balance sheet

Report period2018 2019 2020 2021
End date of the reporting period
Capitalization, CN¥
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Burning Rock Biotech cash flows

Report period2018 2019 2020 2021
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Burning Rock Biotech multipliers

Report period2018 2019 2020 2021
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Burning Rock Biotech profitability

Report period2018 2019 2020 2021
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Burning Rock Biotech assets
Burning Rock Biotech cash flows

Burning Rock Biotech dividend policy

The company doesn't provide dividend

Burning Rock Biotech shares

TickerNameTypeNominal valueISINPrice
BNR:USBurning Rock BiotechCommon share-US12233L1070$0.777
Burning Rock Biotech news
31.05.2022
Burning Rock Biotech's IFRS loss for 3 months of 2022 was CN¥261.388 million, up 52.5% from CN¥171.411 million in the previous year. Revenue increased 27.1% to CN¥135,524 million versus CN¥106,623 million a year earlier.
Source: {source} pictogram ir.brbiotech.com
Pictogram next
22.03.2022
Burning Rock Biotech's IFRS loss for 2021 was CN¥796.697 million, up 95.6% from CN¥407.235 million in the previous year. Revenue increased 18.1% to CN¥507.862 million versus CN¥429.903 million a year earlier.
Source: {source} pictogram ir.brbiotech.com
Pictogram next
16.11.2021
Burning Rock Biotech's IFRS loss for 9M 2021 was CN¥545.553 million, up 2.2 times from CN¥250.757 million in the previous year. Revenue increased 20.9% to CN¥360.517 million from CN¥298.181 million a year earlier.
Source: {source} pictogram ir.brbiotech.com
Pictogram next
31.08.2021
Burning Rock Biotech's loss under IFRS for 6M 2021 was CN¥375.076 million, up three times from CN¥123.627 million in the previous year. Revenue increased 34.2% to CN¥233.902 million from CN¥174.3 million a year earlier.
Source: {source} pictogram ir.brbiotech.com
Pictogram next
All Burning Rock Biotech news
General information
Company nameBurning Rock Biotech
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address5th Floor Building 1 No138 Xinjun Ring Road Shanghai China
Mailing address5th Floor Building 1 No138 Xinjun Ring Road Shanghai China
Websitebrbiotech.gcs-web.com
Information disclosurewww.sec.gov